Norges Bank Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,125,933 shares of the biopharmaceutical company’s stock, valued at approximately $802,036,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Amundi boosted its position in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after purchasing an additional 393,997 shares during the period. Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. Finally, Thrivent Financial for Lutherans raised its position in Regeneron Pharmaceuticals by 1,272.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company’s stock worth $89,179,000 after purchasing an additional 116,074 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on REGN. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Down 0.7 %

Shares of REGN stock opened at $635.83 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $629.02 and a 52-week high of $1,211.20. The company has a 50-day simple moving average of $684.76 and a two-hundred day simple moving average of $803.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $69.51 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $11.86 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.